Related Experiment Video
Updated: Mar 3, 2026
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
Image-guided, urethra-sparing transperineal radiofrequency ablation for benign prostatic hyperplasia: a prospective
Thiago Franchi Nunes1, Denis Szejnfeld2, Públio Cesar Cavalcante Viana3
1Interventix, Rua Dr. Antônio Alves Arantes, Campo Grande, Brazil.
Purpose:
To evaluate the feasibility, reproducibility, and clinical outcomes of an image-guided, urethra-sparing transperineal radiofrequency ablation (TPTA) strategy for benign prostatic hyperplasia (BPH) in an outpatient interventional radiology setting.
Methods:
This was a prospective, bicenter, non-randomized study of consecutive men with moderate-to-severe lower urinary tract symptoms (LUTS) refractory or intolerant to medication treated with ultrasound-guided, urethra-sparing TPTA. Outcomes included the International Prostate Symptom Score (IPSS), quality of life, maximum urinary flow rate (Qmax), post-void residual volume (PVR), prostate volume, prostate-specific antigen (PSA), and ejaculatory function [assessed using the Male Sexual Health Questionnaire-Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF)]; complications were graded using the Clavien-Dindo classification. The primary endpoint was a 12-month change in ejaculatory function; secondary endpoints included composite clinical response (≥ 30% IPSS reduction without retreatment) and urinary and structural changes.
Results:
At 12 months, clinically meaningful improvements were observed across patient-reported symptoms and concordant objective functional and anatomical parameters in a carefully selected outpatient cohort. The median IPSS decreased from 19.5 at baseline to 5.0 at 6 months and 4.0 at 12 months (P < 0.001), accompanied by sustained increases in the Qmax and reductions in PVR, prostate volume, and PSA (all P < 0.001). Among sexually active men, MSHQ-EjD-SF function scores remained stable during the follow-up period, and antegrade ejaculation was preserved in 90% of patients. The composite clinical response rate (≥ 30% IPSS reduction without retreatment) was 97.1% at both 6 and 12 months, with no device-related Clavien-Dindo ≥ III complications observed.
Conclusion:
These findings suggest that image-guided, urethra-sparing TPTA is a reproducible outpatient interventional radiology procedure capable of achieving clinically meaningful symptom relief while preserving ejaculatory function, supporting further comparative and multicenter evaluation.
Clinical Significance:
Urethra-sparing TPTA has proven to be a safe, feasible, and effective treatment for LUTS and may represent a minimally invasive and effective alternative for BPH.
